CN110787282A - Chloasma skin compound preparation and using method thereof - Google Patents
Chloasma skin compound preparation and using method thereof Download PDFInfo
- Publication number
- CN110787282A CN110787282A CN201911058535.3A CN201911058535A CN110787282A CN 110787282 A CN110787282 A CN 110787282A CN 201911058535 A CN201911058535 A CN 201911058535A CN 110787282 A CN110787282 A CN 110787282A
- Authority
- CN
- China
- Prior art keywords
- compound preparation
- injection
- chloasma
- skin
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 55
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 206010008570 Chloasma Diseases 0.000 title claims abstract description 31
- 208000003351 Melanosis Diseases 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 21
- 238000002347 injection Methods 0.000 claims abstract description 43
- 239000007924 injection Substances 0.000 claims abstract description 43
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- 210000003491 skin Anatomy 0.000 claims abstract description 27
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 17
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 17
- 239000011718 vitamin C Substances 0.000 claims abstract description 17
- 108010024636 Glutathione Proteins 0.000 claims abstract description 16
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 14
- 239000002131 composite material Substances 0.000 claims abstract description 8
- 210000004207 dermis Anatomy 0.000 claims abstract description 7
- 238000007865 diluting Methods 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 12
- 230000003902 lesion Effects 0.000 claims description 7
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 8
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 4
- 230000019612 pigmentation Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000012423 maintenance Methods 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 239000007863 gel particle Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical group C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a chloasma skin composite preparation and a using method thereof, which are characterized in that: the chloasma skin compound preparation comprises vitamin C for injection, reduced glutathione for injection and medical sodium hyaluronate gel, wherein the weight ratio of the vitamin C for injection to the reduced glutathione for injection is 1: 2:1, preparing a compound preparation, wherein the using method comprises the following steps: 1) preparing a composite preparation; 2) diluting the composite preparation; 3) locating points in the dermis; 4) and carrying out precise microdroplet injection. Compared with the prior art, the invention has the advantages that: the invention uses the compound preparation local intracutaneous microdroplet injection technology to ablate chloasma, has definite effect, the effective rate of 90 percent, high safety, accurate effect, accurate dosage, small influence on the whole body, no wound, no recovery period of pigmentation and long maintenance time in the later period.
Description
Technical Field
The invention relates to the field of medical skin care, in particular to a chloasma skin composite preparation and a using method thereof.
Background
In the traditional method for treating chloasma, the effect of an externally-applied product is not exact, the duration is short, the side effect of an oral medicine on the whole body is large and the effect is not obvious, and the side effect of medical laser local treatment is traumatic and easily causes pigmentation and the like.
Disclosure of Invention
The invention aims to solve the technical problem of providing a chloasma skin composite preparation and a using method thereof.
In order to solve the technical problems, the technical scheme provided by the invention is as follows: the compound preparation of chloasma skin and the use method thereof are characterized in that: the chloasma skin compound preparation comprises vitamin C for injection, reduced glutathione for injection and medical sodium hyaluronate gel, wherein the weight ratio of the vitamin C for injection to the reduced glutathione for injection is 1: 2:1, preparing a compound preparation, wherein the using method comprises the following steps:
1) preparing a composite preparation: vitamin C for injection, reduced glutathione for injection, medical sodium hyaluronate gel, 1: 2:1, preparing a compound preparation;
2) and diluting the compound preparation: diluting the compound preparation 10 times with 0.9% physiological saline;
3) and inner fixed point of the real layer skin: accurately fixing the spot on the dermis layer of the skin area of the chloasma lesion by using a 30G superfine sharp needle;
4) and accurate droplet injection: each spot was injected with 0.05 ml of diluted drug.
Compared with the prior art, the invention has the advantages that: the invention uses the compound preparation local intracutaneous microdroplet injection technology to ablate chloasma, has definite effect, the effective rate of 90 percent, high safety, accurate effect, accurate dosage, small influence on the whole body, no wound, no recovery period of pigmentation and long maintenance time in the later period.
As an improvement, the compound preparation of the chloasma skin comprises three kinds of medicine injection, namely vitamin C for injection, reduced glutathione for injection and medical sodium hyaluronate gel, and is prepared into the compound preparation.
As an improvement, the diluted compound preparation adopts 0.9 percent of normal saline to dilute the compound preparation by 10 times.
As an improvement, the application method of the diluted compound preparation adopts a 30G superfine sharp needle to precisely determine points in the dermis layer of the chloasma lesion skin.
As an improvement, the application method of the diluted compound preparation adopts 0.05 ml of the diluted medicine after accurate injection.
Drawings
Fig. 1 is a flow chart of a compound preparation of chloasma skin and a using method thereof.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings.
The invention is concretely implemented, a compound preparation of chloasma skin and a using method thereof, and is characterized in that: the chloasma skin compound preparation comprises vitamin C for injection, reduced glutathione for injection and medical sodium hyaluronate gel, wherein the weight ratio of the vitamin C for injection to the reduced glutathione for injection is 1: 2:1, preparing a compound preparation, wherein the using method comprises the following steps:
1) preparing a composite preparation: vitamin C for injection, reduced glutathione for injection, medical sodium hyaluronate gel, 1: 2:1, preparing a compound preparation;
2) and diluting the compound preparation: diluting the compound preparation 10 times with 0.9% physiological saline;
3) and inner fixed point of the real layer skin: accurately fixing the spot on the dermis layer of the skin area of the chloasma lesion by using a 30G superfine sharp needle;
4) and accurate droplet injection: each spot was injected with 0.05 ml of diluted drug.
The compound preparation of the chloasma skin comprises three kinds of medicine injection, namely vitamin C for injection, reduced glutathione for injection and medical sodium hyaluronate gel, and is prepared into the compound preparation.
The diluted compound preparation adopts 0.9 percent physiological saline to dilute the compound preparation by 10 times.
The application method of the diluted compound preparation adopts a 30G superfine sharp needle to precisely determine points in the dermis layer of the chloasma lesion skin.
The application method of the diluted compound preparation adopts 0.05 ml of the diluted medicine which is accurately injected.
The working principle of the invention is as follows: the invention combines vitamin C for injection, glutathione for injection, medical sodium hyaluronate gel and 30G superfine sharp needle, adopts the technology of intradermal superficial layer targeted precise microdroplet injection to inject the medicine into the chloasma lesion area, and effectively reduces the chloasma color depth and area size on the whole.
Vitamin C for injection, also known as L-ascorbic acid, is white or off-white powder or crystalline powder, and is a vitamin drug. Vitamin C participates in amino acid metabolism, synthesis of neurotransmitter, synthesis of collagen and interstitial tissue, can reduce permeability of capillary, increase resistance to infection, and participate in detoxification function. The topical application to the skin can lighten the pigmentation, which is related to its antioxidant function.
The reduced glutathione for injection is white powder, is a kind of peptide naturally synthesized in human cytoplasm, consists of glutamic acid, cysteine and glycine, contains sulfhydryl (-SH), is widely distributed in various organs of organism, has important function for maintaining cell biological function, and participates in tricarboxylic acid circulation and sugar metabolism in vivo. It can combine with free radical in vivo via sulfhydryl group, thereby accelerating free radical excretion, and can be used for topical application on skin to lighten pigment, and has antioxidant effect.
The medical sodium hyaluronate product consists of a pre-filled glass syringe and gel particle suspension encapsulated in the syringe. The gel particle suspension consists of non-crosslinked sodium hyaluronate (a crosslinking agent is BDDE), lidocaine hydrochloride, sodium chloride, a phosphate buffer system and water for injection, wherein the sodium hyaluronate is prepared by a microbial fermentation method and has a labeled concentration of 23 mg/mL. The syringe encapsulating the gel particle suspension has been moist heat sterilized. The product was "changed" to a single use product consisting of a pre-filled glass syringe and a suspension of gel particles enclosed in the syringe.
Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature, and in the description of the invention, "plurality" means two or more unless explicitly defined otherwise.
In the present invention, unless otherwise specifically stated or limited, the terms "mounted," "connected," "fixed," and the like are to be construed broadly and may, for example, be fixedly connected, detachably connected, or integrally connected; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meanings of the above terms in the present invention can be understood by those skilled in the art according to specific situations.
In the present invention, unless otherwise expressly stated or limited, "above" or "below" a first feature means that the first and second features are in direct contact, or that the first and second features are not in direct contact but are in contact with each other via another feature therebetween. Also, the first feature being "on," "above" and "over" the second feature includes the first feature being directly on and obliquely above the second feature, or merely indicating that the first feature is at a higher level than the second feature. A first feature being "under," "below," and "beneath" a second feature includes the first feature being directly above and obliquely above the second feature, or simply meaning that the first feature is at a lesser level than the second feature.
In the description herein, reference to the terms "one embodiment," "some embodiments," "an example," "a specific example," or "some examples" or the like means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made in the above embodiments by those of ordinary skill in the art without departing from the principle and spirit of the present invention.
Claims (5)
1. The compound preparation of chloasma skin and the use method thereof are characterized in that: the chloasma skin compound preparation comprises vitamin C for injection, reduced glutathione for injection and medical sodium hyaluronate gel, wherein the weight ratio of the vitamin C for injection to the reduced glutathione for injection is 1: 2:1, preparing a compound preparation, wherein the using method comprises the following steps:
1) preparing a composite preparation: vitamin C for injection, reduced glutathione for injection, medical sodium hyaluronate gel, 1: 2:1, preparing a compound preparation;
2) and diluting the compound preparation: diluting the compound preparation 10 times with 0.9% physiological saline;
3) and inner fixed point of the real layer skin: accurately fixing the spot on the dermis layer of the skin area of the chloasma lesion by using a 30G superfine sharp needle;
4) and accurate droplet injection: each spot was injected with 0.05 ml of diluted drug.
2. The compound preparation for treating chloasma as claimed in claim 1, which comprises: the compound preparation of the chloasma skin comprises three kinds of medicine injection, namely vitamin C for injection, reduced glutathione for injection and medical sodium hyaluronate gel, and is prepared into the compound preparation.
3. The compound preparation for treating chloasma as claimed in claim 1, which comprises: the diluted compound preparation adopts 0.9 percent physiological saline to dilute the compound preparation by 10 times.
4. The compound preparation for treating chloasma as claimed in claim 1, which comprises: the application method of the diluted compound preparation adopts a 30G superfine sharp needle to precisely determine points in the dermis layer of the chloasma lesion skin.
5. The compound preparation for treating chloasma as claimed in claim 1, which comprises: the application method of the diluted compound preparation adopts 0.05 ml of the diluted medicine which is accurately injected.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911058535.3A CN110787282A (en) | 2019-11-01 | 2019-11-01 | Chloasma skin compound preparation and using method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911058535.3A CN110787282A (en) | 2019-11-01 | 2019-11-01 | Chloasma skin compound preparation and using method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110787282A true CN110787282A (en) | 2020-02-14 |
Family
ID=69440706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911058535.3A Pending CN110787282A (en) | 2019-11-01 | 2019-11-01 | Chloasma skin compound preparation and using method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110787282A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011460A (en) * | 2007-02-06 | 2007-08-08 | 朱炜 | Pharmaceutical composition with both depigmenting and whitening effects |
| US20140039061A1 (en) * | 2011-02-03 | 2014-02-06 | Q-Med Ab | Hyaluronic acid composition |
| US20190022182A1 (en) * | 2015-12-15 | 2019-01-24 | Medicell Technologies, Llc | Stem cell stimulating compositions and methods of treating melasma |
| CN110038192A (en) * | 2018-01-16 | 2019-07-23 | 张健 | A method of facial freckle and chloasma are improved by water laser accunputure injection group |
-
2019
- 2019-11-01 CN CN201911058535.3A patent/CN110787282A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011460A (en) * | 2007-02-06 | 2007-08-08 | 朱炜 | Pharmaceutical composition with both depigmenting and whitening effects |
| US20140039061A1 (en) * | 2011-02-03 | 2014-02-06 | Q-Med Ab | Hyaluronic acid composition |
| US20190022182A1 (en) * | 2015-12-15 | 2019-01-24 | Medicell Technologies, Llc | Stem cell stimulating compositions and methods of treating melasma |
| CN110038192A (en) * | 2018-01-16 | 2019-07-23 | 张健 | A method of facial freckle and chloasma are improved by water laser accunputure injection group |
Non-Patent Citations (2)
| Title |
|---|
| 权腾等: "水光注射三联疗法联合大光斑低能量Q开关1064nm Nd:YAG激光治疗黄褐斑疗效观察" * |
| 陶茂灿等: "还原性谷胱甘肽、维生素C联合中药治疗黄褐斑223例疗效观察" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9173921B1 (en) | Method of promoting hair growth by administration of bFGF | |
| CN108025185A (en) | Method for the topical application for strengthening beneficial agent | |
| CN105848640A (en) | Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent | |
| CN104473966A (en) | Electricity-generating particulates and the use thereof | |
| CN106176292A (en) | A kind of biodegradable injection molding process decorative material and preparation method thereof | |
| CN111195230B (en) | Method for preparing flexible liposome | |
| CN107260569A (en) | A kind of preparation method of eye-care compositions liposome | |
| CN108384742A (en) | A kind of novel activated dose and preparation method thereof for immune cell expansion | |
| CN100379446C (en) | Erythropoietin ameliorates chemotheapy-induced toxicity in vivo | |
| ES2932550T3 (en) | Stem cell stimulating compositions and methods for treating melasma | |
| US20120237612A1 (en) | Ultrasound Gel And Methods Of Manufacturing Same | |
| EP1982703A2 (en) | A transpulmonary composition | |
| WO2009116556A1 (en) | Pharmaceutical composition for injection | |
| CN114848577A (en) | Double-layer conductive microneedle patch for treating subcutaneous tumors and preparation method and application thereof | |
| WO2017177184A1 (en) | Removable tattoo ink and method of producing same | |
| CN103463627A (en) | Oral care composition containing heat-resistant superoxide dismutase and growth factors | |
| CN110787282A (en) | Chloasma skin compound preparation and using method thereof | |
| CN108186571A (en) | Reversible crosslink asymmetry vesica is preparing the application in treating acute leukemia drug | |
| CN101156849B (en) | An alepsin slow-releasing gel for promoting paradontal part reborn as well as preparation method and application | |
| CN103860444B (en) | Contain the siRNA cell culture cleawhite over-night essences for suppressing melanin generation | |
| CN108697639A (en) | A kind of percutaneous absorbtion composition and its purposes in preparing transdermal formulation | |
| CN111388761B (en) | Application of gastrodin in medical titanium metal use in diabetes environment | |
| CN107951868B (en) | Muscone patch and preparation method and application thereof | |
| CN109498547A (en) | A kind of Local injection of Bleomycin A_5 preparation and preparation method thereof | |
| CN110755627A (en) | Temperature-sensitive drug delivery material in liquid state at 4 ℃ and solid state at 37 DEG C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200214 |
|
| WD01 | Invention patent application deemed withdrawn after publication |